XNCRXencor
About Xencor
Xencor (NASDAQ:XNCR) focuses on developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma, and allergic diseases. The company's technology platform is designed to improve the function and clinical utility of antibody therapeutics. Xencor’s pipeline includes novel antibody candidates currently in clinical development, aimed at providing new treatment options for patients in need. With a commitment to innovation, Xencor's objective is to leverage its XmAb® technology platform to create and develop advanced therapeutic antibodies that can potentially transform the way diseases are treated.
What is XNCR known for?
Snapshot
Public US
Ownership
1997
Year founded
285
Employees
California, United States
Head office
1 of 5
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
United States
Produtos e/ou serviços de Xencor
- XmAb antibody engineering platform, a suite of technologies for improving antibody drug properties.
- Tidutamab, an investigational bispecific antibody targeting CD3 and solid tumor antigen for cancer therapy.
- Plamotamab, a CD20 x CD3 bispecific antibody designed for the treatment of B-cell malignancies.
- Vibecotamab, a bispecific antibody targeting CD123 and CD3 for acute myeloid leukemia.
- Obexelimab, designed to target B-cell signaling for autoimmune diseases.
- XmAb717, an innovative bispecific antibody for the treatment of various cancers.
equipe executiva do Xencor
- Dr. Bassil I. Dahiyat Ph.D.Co-Founder, CEO, President & Director
- Mr. Bart Jan CornelissenSenior VP & CFO
- Dr. John R. Desjarlais Ph.D.Executive VP of Research & Chief Scientific Officer
- Ms. Celia E. Eckert J.D.Senior VP, General Counsel & Corporate Secretary
- Mr. Charles LilesAssociate Director and Head of Corporate Communications & Investor Relations
- Ms. Jennifer SandozSenior VIce President of Human Resources
- Mr. Kirk Rosemark RACSenior Vice President of Regulatory Affairs & Quality Assurance
- Mr. Eric P. KowackSenior Vice President of Program Leadership & Alliance Management
- Mr. Dane Vincent Leone C.F.A.Executive VP & Chief Strategy Officer
- Dr. Mark Osterman M.D.Senior Vice President of Clinical Development (Autoimmune)